CG Oncology’s Cretostimogene Shows Promising Results in Bladder Cancer Trial
CG Oncology, Inc. (NASDAQ:CGON) announced positive results from its Phase 3 BOND-003 trial for patients with high-risk non-muscle invasive bladder cancer. The study showed a complete response rate of 75.5% at any time, with 34 confirmed responses and nine patients still awaiting their 24-month assessment. The trial demonstrated significant efficacy in patients who were unresponsive … Read more